Aarti Drugs Q4 FY26 Results: Analysts Watch Revenue and PAT Trends
- March 9, 2026
- Posted by: Neeraj Pandey
- Category: Uncategorized
Aarti Drugs Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Aarti Drugs was listed on the National Stock Exchange (NSE) on 19-Sep-2003. Aarti Drugs share has its face value of 10 per share, and its NSE symbol is AARTIDRUGS. The company operates in the Healthcare sector and primarily belongs to the Pharmaceuticals industry.
Aarti Drugs Q4 Results 2026 Preview
- Aarti Drugs Q4 FY26 revenue is expected to be around Moderate Growth Expected, representing a 10-14% YoY increase compared to the same quarter last year.
- Profit After Tax, or PAT, is projected to rise 11-16% YoY.
- EBITDA to rise 12.50%.
- Aarti Drugs is expected to show Moderate Growth Expected in its revenue.
Click and Sign Up to Get Live Updates on Q4 Results
Aarti Drugs Share Performance
- Over the past six months, Aarti Drugs share price has 21% by 10-15% to 345.2.
- Moreover, over the past year, the stock has 35% by Up
- Despite this weak short-term performance, Aarti Drugs stock has delivered a financially sound 170% return over the past 5 years.
- As of today, 09-03-2026, the Aarti Drugs share price is trading at 345.2 per share.
Key Factors to Watch for Aarti Drugs Q4 Results FY26
- Revenue Growth & Segment Performance – Focus on topline growth in the Pharmaceuticals industry within the Healthcare sector.
- Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
- Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
- Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
- Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.
About Aarti Drugs
Aarti Drugs is a pharmaceutical manufacturer focused on active pharmaceutical ingredients, intermediates, and specialty chemicals. Serving both Indian and global markets, it is known for its portfolio in antibiotics, anti-protozoal, and anti-inflammatory products, catering to diverse healthcare needs.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Final Thoughts
Aarti Drugs is gear up to announce its Q4 FY26 results. Analysts expect 10-14% revenue growth, a 11-16% rise in PAT, and a 12.50% rise in EBITDA. Aarti Drugs focuses on revenue growth from order execution, margin improvement, a strong order book, and management.
Stay informed with Univest blogs to get real-time updates on Aarti Drugs Q4 results FY26.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Recent Articles
Aadhar Housing Finance Gears Up for Q4 Reveal. Check Key Expectations Here
Aakash Exploration Services Gears Up for Q4 Reveal. Check Key Expectations Here
Aarey Drugs & Pharmaceuticals Gears Up for Q4 Reveal. Check Key Expectations Here
Aarnav Fashions Gears Up for Q4 Reveal. Check Key Expectations Here
Aaron Industries Gears Up for Q4 Reveal. Check Key Expectations Here
